Determinants of implementation of continuous glucose monitoring for patients with Insulin-Treated type 2 diabetes: a national survey of primary care providers

影响胰岛素治疗型 2 型糖尿病患者实施持续血糖监测的因素:一项针对初级保健提供者的全国性调查

阅读:1

Abstract

OBJECTIVES: To identify determinants of continuous glucose monitoring (CGM) implementation from primary care providers' (PCPs') perspectives and examine the associations of these determinants with both PCP intent to discuss CGM with eligible patients and facility-level uptake of CGM. STUDY DESIGN: Cross-sectional survey. METHODS: A survey about CGM implementation for patients with type 2 diabetes on insulin was distributed to all PCPs in the Department of Veterans Affairs (VA) health system from October 2023-April 2024. Multi-item scales measured perceived clinical benefits of CGM, workload capacity, knowledge about CGM, access to CGM resources, and support from leadership and other services. Responses were on a 5-point Likert scale from "Strongly Disagree" to "Strongly Agree". An item asked about likelihood of initiating discussions about starting CGM. Facility-level uptake was measured using VA administrative data. Multivariable regression models assessed the relationship between determinants of CGM implementation and both PCP intent to discuss CGM and facility-level uptake. RESULTS: Of 1373 respondents, most perceived clinical benefits of CGM (79% "Agree" + "Strongly Agree"). Very few indicated sufficient access to resources (8%) and support from leadership & other services (5%). After adjustment for respondent characteristics, the scale most strongly associated with PCP intent to discuss CGM was PCP Knowledge About CGM (B = 0.54, P <.001). Facility uptake of CGM was associated with Clinical Benefits of CGM (B = 0.10, P =.026) and Support from Leadership & Other Services (B = 0.18, P <.001). CONCLUSIONS: PCPs perceive benefits to CGM but lack sufficient knowledge, resources, and workload capacity to manage it alone. PCP education about CGM use and interprofessional support for uptake may increase the likelihood that eligible patients use CGM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。